 Shares of Mallinckrodt NYSE:MNK were unchanged in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share decreased 15.46 over the past year to 1.64, which beat the estimate of 1.48.Revenue of 665,800,000 less by 15.79 year over year, which missed the estimate of 693,310,000.Looking Ahead Earnings guidance hasnt been issued by the company for now.Revenue guidance hasnt been issued by the company for now.Details Of The Call Date: May 05, 2020View more earnings on MNKWebcast URL: Action 52-week high: 17.4052-week low: 1.00Price action over last quarter: down 16.03Company Description Mallinckrodt PLC develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands that includes innovative specialty pharmaceutical brands; and Specialty Generics that includes niche specialty generic drugs and active pharmaceutical ingredients.See more from Benzinga 16 Healthcare Stocks Moving In Mondays Pre-Market Session 20 Healthcare Stocks Moving In Wednesdays Pre-Market SessionC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 